Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Daiichi-Sankyo will introduce new anti-coagulant
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Jul 22, 2014 05:50:39
Daiichi-Sankyo expects its new anti-coagulant edoxaban will be launched before the end of 2016.

Edoxaban’s indications will be the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF) and the treatment of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent VTE. Clinical studies proved that edoxaban is safer than warfarin and as effective as warfarin.

An official of Daiichi-Sankyo said, “Edoxaban is taken once daily. It met major clinical standards in a large clinical trial. It is competitive enough.”

Currently Pradaxa, Xarelto, and Eliquis are approved for marketing in South Korea.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com